Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP.

JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880. Review.

PMID:
22203539
2.

Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.

Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T.

Thromb Res. 2015 Mar;135(3):449-58. doi: 10.1016/j.thromres.2014.12.007. Review.

PMID:
25511576
3.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Review.

4.

Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment [Internet].

Dahabreh IJ, Moorthy D, Lamont JL, Chen ML, Kent DM, Lau J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Sep.

5.

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.

Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R.

Heart. 2012 Jan;98(2):100-8. doi: 10.1136/hrt.2011.227652. Review.

PMID:
21693476
6.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

7.

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.

Li Y, Tang HL, Hu YF, Xie HG.

J Thromb Haemost. 2012 Feb;10(2):199-206. doi: 10.1111/j.1538-7836.2011.04570.x. Review.

8.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
9.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium..

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Review. No abstract available.

10.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Review.

PMID:
22207144
11.

Clopidogrel and proton pump inhibitors--where do we stand in 2012?

Drepper MD, Spahr L, Frossard JL.

World J Gastroenterol. 2012 May 14;18(18):2161-71. doi: 10.3748/wjg.v18.i18.2161. Review.

12.

Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.

Sorich MJ, Polasek TM, Wiese MD.

Clin Pharmacol Ther. 2013 Sep;94(3):376-82. doi: 10.1038/clpt.2013.100. Review.

PMID:
23670120
13.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Review.

PMID:
21592545
14.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
15.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
16.

A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.

Osnabrugge RL, Head SJ, Zijlstra F, ten Berg JM, Hunink MG, Kappetein AP, Janssens AC.

Genet Med. 2015 Jan;17(1):3-11. doi: 10.1038/gim.2014.76. Review.

PMID:
24946154
17.

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?

Kassimis G, Stavrou EF, Alexopoulos D, Athanassiadou A.

Curr Pharm Des. 2013;19(13):2489-95. Review.

PMID:
23360266
18.

Proton pump inhibitors and clopidogrel.

Gaglia MA Jr, Waksman R.

Cardiovasc Ther. 2010 Jun;28(3):169-76. doi: 10.1111/j.1755-5922.2010.00143.x. Review.

PMID:
20345494
19.

[Antiplatelet therapy in coronary heart disease. Some problems and achivements].

Gratsianskiĭ NA.

Kardiologiia. 2010;50(6):4-21. Review. Russian.

PMID:
20659022
20.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR.

Pharmacogenomics. 2009 Nov;10(11):1799-817. doi: 10.2217/pgs.09.143. Review.

PMID:
19891556
Items per page

Supplemental Content

Support Center